Baricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Baricitinib may be used as monotherapy or in combination with Methotrexate.
لا يُسمح بإعادة نشر المحتوى دون إذن من المؤلف.
Baricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Baricitinib may be used as monotherapy or in combination with Methotrexate.
تغذية راجعة
الإبلاغ
لا يُسمح بإعادة نشر المحتوى دون إذن من المؤلف.
تغذية راجعة
الإبلاغ